A blanket protocol to study oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewing-like sarcomas

Administered By

Duke Cancer Institute

Awarded By

Sarcoma Alliance for Research Through Collaboration

Contributors

Riedel, Richard Francis Principal Investigator

Start/End

February 1, 2014 - July 13, 2021